Brief: Amneal Announces Expanded Coverage For Crexont® To Enhance Access For Parkinson’S Disease Patients In The U.S.
03/04/2025 13:09
April 3 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL ANNOUNCES EXPANDED COVERAGE FOR CREXONT® (CARBIDOPA AND LEVODOPA) TO ENHANCE ACCESS FOR PARKINSON’S DISEASE PATIENTS IN THE U.S. Source text: ID:nBw4yQPKPa Further company coverage: AMRX.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study